Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.
作者信息
Stasch Johannes-Peter, Pacher Pál, Evgenov Oleg V
机构信息
Institute of Pharmacy, Martin Luther University, Halle, and the Cardiology Research, Bayer HealthCare AG, Wuppertal, Germany.
出版信息
Circulation. 2011 May 24;123(20):2263-73. doi: 10.1161/CIRCULATIONAHA.110.981738.
Abstract
摘要
相似文献
1
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.可溶性鸟苷酸环化酶作为心肺疾病中一个新兴的治疗靶点。
Circulation. 2011 May 24;123(20):2263-73. doi: 10.1161/CIRCULATIONAHA.110.981738.
2
Tricyclic indole and dihydroindole derivatives as new inhibitors of soluble guanylate cyclase.三环吲哚和二氢吲哚衍生物作为可溶性鸟苷酸环化酶的新型抑制剂
Bioorg Med Chem Lett. 2009 Aug 15;19(16):4810-3. doi: 10.1016/j.bmcl.2009.06.047. Epub 2009 Jun 14.
3
Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.在心血管疾病中使用BAY 41-2272对可溶性鸟苷酸环化酶进行不依赖一氧化氮的刺激。
Cardiovasc Drug Rev. 2007 Spring;25(1):30-45. doi: 10.1111/j.1527-3466.2007.00003.x.
4
A new small molecule inhibitor of soluble guanylate cyclase.一种新型的可溶性鸟苷酸环化酶小分子抑制剂。
Bioorg Med Chem. 2015 Sep 1;23(17):5303-10. doi: 10.1016/j.bmc.2015.07.074. Epub 2015 Aug 4.
5
[Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].利奥西呱：可溶性鸟苷酸环化酶刺激剂。治疗肺动脉高压和无法手术的慢性血栓栓塞性肺动脉高压的新作用模式
Pneumologie. 2015 Mar;69(3):135-43. doi: 10.1055/s-0034-1391435. Epub 2015 Mar 6.
6
cGMP becomes a drug target.环磷酸鸟苷成为一种药物靶点。
Naunyn Schmiedebergs Arch Pharmacol. 2012 Mar;385(3):243-52. doi: 10.1007/s00210-012-0730-6.
7
Activation and up-regulation of spinal cord nitric oxide receptor, soluble guanylate cyclase, after formalin injection into the rat hind paw.将福尔马林注射到大鼠后爪后脊髓一氧化氮受体、可溶性鸟苷酸环化酶的激活与上调
Neuroscience. 2002;112(2):439-46. doi: 10.1016/s0306-4522(02)00075-1.
8
Surface plasmon resonance using the catalytic domain of soluble guanylate cyclase allows the detection of enzyme activators.表面等离子体共振利用可溶性鸟苷酸环化酶的催化结构域可检测到酶的激活剂。
Bioorg Med Chem Lett. 2014 Feb 15;24(4):1075-9. doi: 10.1016/j.bmcl.2014.01.015. Epub 2014 Jan 13.
9
Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonism.抑制纹状体可溶性鸟苷酸环化酶-cGMP 信号转导可逆转帕金森病动物模型的基底神经节功能障碍和运动不能。
PLoS One. 2011;6(11):e27187. doi: 10.1371/journal.pone.0027187. Epub 2011 Nov 2.
10
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.靶向可溶性鸟苷酸环化酶治疗肺动脉高压。
Expert Rev Respir Med. 2011 Apr;5(2):153-61. doi: 10.1586/ers.11.9.
引用本文的文献
1
The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice.维立西呱在心力衰竭治疗中的作用：从临床试验到临床实践
Rev Cardiovasc Med. 2025 Aug 29;26(8):39886. doi: 10.31083/RCM39886. eCollection 2025 Aug.
2
Optimal Timing of Vericiguat Therapy in Patients with Heart Failure with Reduced/Mildly Reduced Ejection Fraction for Improving Mortality and Heart Failure Re-Hospitalization Rate.在射血分数降低/轻度降低的心力衰竭患者中，维立西呱治疗改善死亡率和心力衰竭再住院率的最佳时机
J Clin Med. 2025 Aug 19;14(16):5856. doi: 10.3390/jcm14165856.
3
Analysis of research trends and development prospects of soluble guanylate cyclase stimulators/activators: using bibliometric methods.可溶性鸟苷酸环化酶刺激剂/激活剂的研究趋势与发展前景分析：运用文献计量学方法
Front Pharmacol. 2025 Jun 10;16:1501330. doi: 10.3389/fphar.2025.1501330. eCollection 2025.
4
Vascular (dys)function in the failing heart.衰竭心脏中的血管（功能失调）功能
Nat Rev Cardiol. 2025 Jun 22. doi: 10.1038/s41569-025-01163-w.
5
Influence of Soluble Guanylate Cyclase on Cardiac, Vascular, and Renal Structure and Function: A Physiopathological Insight.可溶性鸟苷酸环化酶对心脏、血管和肾脏结构与功能的影响：生理病理学见解
Int J Mol Sci. 2025 May 9;26(10):4550. doi: 10.3390/ijms26104550.
6
Neuroprotective Effect of a Novel Soluble Guanylate Cyclase Activator Runcaciguat in Diabetic and Ischemic Retinopathy.新型可溶性鸟苷酸环化酶激活剂伦卡西呱对糖尿病性和缺血性视网膜病变的神经保护作用
Diabetes. 2025 Jul 1;74(7):1220-1232. doi: 10.2337/db24-0739.
7
In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy.心脏肿瘤学中心血管-肾脏-代谢综合征时代：从发病机制到预防与治疗
Cancers (Basel). 2025 Mar 30;17(7):1169. doi: 10.3390/cancers17071169.
8
Short-term outpatient follow-up of vericiguat treatment in patients hospitalized for heart failure.因心力衰竭住院患者接受维立西呱治疗的短期门诊随访
Front Cardiovasc Med. 2025 Mar 4;12:1465700. doi: 10.3389/fcvm.2025.1465700. eCollection 2025.
9
Vericiguat prevents high glucose-mediated impaired vascular smooth muscle cGMP production and vasorelaxation.维立西呱可预防高糖介导的血管平滑肌环磷酸鸟苷（cGMP）生成受损及血管舒张功能障碍。
Sci Rep. 2025 Feb 10;15(1):4939. doi: 10.1038/s41598-025-88938-w.
10
Shifting Paradigms in the Management of Pulmonary Hypertension.肺动脉高压管理中的范式转变
Eur Cardiol. 2024 Dec 23;19:e25. doi: 10.15420/ecr.2024.11. eCollection 2024.
本文引用的文献
1
Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.西那卡塞，一种可溶性鸟苷酸环化酶激活剂，在急性失代偿性心力衰竭中不仅能减轻心脏负荷，还会引起低血压。
Eur Heart J. 2013 Jan;34(1):57-67. doi: 10.1093/eurheartj/ehs196. Epub 2012 Jul 9.
2
Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.肺和全身血管扩张对可溶性鸟苷酸环化酶激活剂 BAY 60-2770 的反应不依赖于内源性一氧化氮或还原血红素。
Am J Physiol Heart Circ Physiol. 2011 Mar;300(3):H792-802. doi: 10.1152/ajpheart.00953.2010. Epub 2011 Jan 7.
3
Dependence of Golgi apparatus integrity on nitric oxide in vascular cells: implications in pulmonary arterial hypertension.血管细胞中高尔基体完整性依赖于一氧化氮：在肺动脉高压中的意义。
Am J Physiol Heart Circ Physiol. 2011 Apr;300(4):H1141-58. doi: 10.1152/ajpheart.00767.2010. Epub 2011 Jan 7.
4
Long-term oral treatment with BAY 41-2272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide-deficient rat model.长期口服 BAY 41-2272 可改善一氧化氮缺乏型大鼠模型的海绵体平滑肌松弛功能障碍。
BJU Int. 2011 Jul;108(1):116-22. doi: 10.1111/j.1464-410X.2010.09776.x. Epub 2010 Oct 15.
5
Pulmonary hypertension with left-sided heart disease.左心疾病相关性肺动脉高压。
Nat Rev Cardiol. 2010 Nov;7(11):648-59. doi: 10.1038/nrcardio.2010.144. Epub 2010 Oct 5.
6
BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.BAY 41-2272 抑制大鼠慢性低氧性肺动脉高压的发展。
Eur J Pharmacol. 2010 Nov 25;647(1-3):147-54. doi: 10.1016/j.ejphar.2010.08.032. Epub 2010 Sep 7.
7
Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.利奥西呱（BAY 63-2521）与华法林：药效学和药代动力学的相互作用研究。
J Clin Pharmacol. 2011 Jul;51(7):1051-60. doi: 10.1177/0091270010378119. Epub 2010 Aug 27.
8
Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure.西那吉特，一种用于急性心力衰竭潜在治疗的可溶性鸟苷酸环化酶激活剂。
Curr Opin Investig Drugs. 2010 Sep;11(9):1039-47.
9
Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.肺和全身血管扩张剂对可溶性鸟苷酸环化酶刺激剂 BAY 41-8543 的反应受一氧化氮调节。
Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1153-9. doi: 10.1152/ajpheart.01101.2009. Epub 2010 Jul 16.
10
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.一氧化氮非依赖性刺激可溶性鸟苷酸环化酶可减少实验性低肾素和高肾素模型中的器官损伤。
J Hypertens. 2010 Aug;28(8):1666-75. doi: 10.1097/HJH.0b013e32833b558c.
Zotero 插件